DEEP SEQUENCING FORUM December 5-6, 2018 Auditorium at Merck Research Labs - Boston, MA

Transcription

1 Deep Sequencing and Related Technologies for Drug Development and Clinical Trial Applications Deep sequencing data is of critical importance in complementing phenotypic and clinical data sets to develop more precise diagnostics and drugs that target responder populations. For this forum, we bring together speakers, exhibitors, and attendees focused on innovating with emerging sequencebased technologies to make the next generation of safe and effective therapies. FEATURED SPEAKERS INCLUDE John Landers Associate Professor Neurology University of Massachusetts Medical School Samuel Rulli R&D Scientist Shanrong Zhao Director, Computational Biology and Bioinformatics Pfizer

2 FOCUS FOR 2018 Deep sequencing data is of critical importance in complementing phenotypic and clinical data sets to develop more precise diagnostics and drugs that target responder populations. The adoption of deep sequencing and its applications in drug development and clinical applications has been spurred along by several economic and technology drivers: decreasing costs and increasing speed to acquire sequencing information; ongoing efforts to annotate and mine data on genes and variants; more accurate and data-rich diagnostics for assessment and treatment of diseases; and, perhaps, most important, the focus on medicines precisely designed for targets and pathways. For this forum, we bring together speakers, exhibitors, and attendees focused on innovating with emerging sequence-based technologies to make the next generation of safe and effective therapies.

3 TOPICS EXPECTED TO BE COVERED INCLUDE: Library generation improving the quality and diversity of sequencing libraries Advances in comprehensive genome coverage and sequencing accuracy Genes panels converting target regions to actionable assays Gene profiling through RNA sequencing Advances in WGS, WES, RNA-seq, mirna Nucleic acid imaging assays: in vitro, in vivo informatics and data mining: Ongoing review and updating of annotations Analytics: connecting sequence to mechanisms of actions, drug response Applications: responder stratification, IVDs, or LDTs Gene therapy delivery strategies (e.g., AAV, CAR-T, sirna, antisense, CRISPR-CasX) Impact of regulatory decisions on progress in the field Long-term goal of bridging drug treatments with genetic and genomic data. Understanding genetic data in the bigger picture of clinical assays and personal-family history Sequencing animal model genes and loci for translational science applications Modeling of gene therapy delivery using translational models Big Data mining to identify subtle (e.g., distributed, sparse) multi-gene markers by evaluating large populations Regulatory, reimbursement, and payers/insurances as a way to gain acceptance by healthcare (cost burden) Cancer, including immuno-oncology, pathways, etc. Cardiovascular, Cardiopulmonary Neurosciences Immunology/Inflammatory Diseases Rare Diseases Microbiome Epigenetics Targeted Audience Those working in technologies to generate and analyze data in the field of Genetics, Genomics, Translational Sciences to advance pharma projects Those developing and using applications to leverage genetic/genomic technologies VPs, Executive/Senior Directors, Principal/Senior Scientists in related fields Laboratory and Technology Directors Project Managers (technical, logistical, and transitioning projects to partners) Technology leaders and researchers (assays, platforms, informatics) Researchers in assays, diagnostics (basic, development, validation, execution) VPs, Executive/Senior Directors, Directors, and Associates in licensing and regulatory

4 Speakers Day 1 Transitioning Discoveries in ALS Genetics to Therapeutic Treatments John Landers, Associate Professor Neurology University of Massachusetts Medical School Application of Sequencing Data in Pre-Clinical Drug Development in Oncology Julia Schüler, Research Director Charles River Discovery Research Services High Throughput, Reduction Transcriptomics, using Ultraplex RNA Sequencing Samuel Rulli, R&D Scientist Comparative Mendelian Genomics and Disease Modeling in Mice Laura Reinholdt, Associate Professor The Jackson Laboratory Evaluation of two main RNA-seq approaches for gene quantification in clinical RNA sequencing: polya+ selection versus rrna depletion Shanrong Zhao, Director, Computational Biology and Bioinformatics Pfizer Gene Therapy in Charcot-Marie-Tooth type 4J Cat Lutz, Senior Director, In Vivo Pharmacology The Jackson Laboratory DNBseq, a proven & robust high-throughput next-generation sequencing technology Zhonghui Peng, Application Scientist BGI Americas QIAseq FastSelect: One-step, rapid removal of rrna during whole transcriptome NGS Library Prep Jonathan Shaffer, Associate Director, NGS Assay Product Development

5 Speakers Day 2 Successfully Leveraging Gene Expression for Biomarker Discovery Leeona Galligan, VP UK Operations Almac Diagnostics SeqPlus Unlocking the true value in FFPE Samples, Enabling More Efficient Genome & Exome Sequencing Richard Williams, Managing Director, Head of Oncology Programs WuXi NextCODE From Coverage to Reimbursement: Coverage and reimbursement for new technology Laurie Howard, Vice President, Policy and Payer Relations LabCorp Abundant, Ultra-Short Trans-Renal Tumor DNA Fragments in Urine For Non-Invasive Cancer Detection and Monitoring Qing Kang, Senior Scientist in Translational Medicine Syros Pharmaceuticals Speeding up Genomic Data Creation, Aggregation and Impactful Interpretation James Flynn, Scientific Engagement Manager Illumina Early Assessment of Treatment Response in Solid Tumors via Quantitating Circulating Tumor DNA Max Ma, Director, Medical Affairs Roche Sequencing Solutions WORKSHOP: Understanding Innate Anti-PD-1 Resistance Therapy in Melanoma Through Integrative Transcriptome Analysis Using ArraySuite (AS) and Ingenuity Pathway Analysis (IPA) Qian Dong, Bioinformatics DIAMOND SPONSOR PLATINUM SPONSORS

6 READY TO REGISTER? 3 EASY WAYS TO BOOK TEL: DEEPSEQUENCINGFORUM@PLANETCONNECT.COM SECURE YOUR PLACE Package Details Pre-Event Registration At The Door Conference Only $1, $1,695 Academic, Government and non-employed/retired discounts for Attendee Passes are available on request. Will you submit a poster? You will receive a $50 discount off the total price. Each Attendee pass includes access to all talks, meals and other activities, including any pre-conference Workshops. REGISTER 3 ATTENDEES AND GET A 4TH ATTENDEE FREE. VENUE Merck Research Laboratories 33 Avenue Louis Pasteur Boston, MA TERMS & CONDITIONS Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to afuture conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time. Changes to Conference & Agenda: PlanetConnect reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. PlanetConnect is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities. Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: deepsequencingforum@planetconnect.com